Search Results

Prevention of Type 2 diabetes: fact or fiction?

Author: Chiasson, Jean-Louis

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 18, December 2007 , pp. 3147-3158(12)

Publisher: Informa Healthcare

The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients

Authors: Sahin, Mustafa; Tanaci, Nedret; Yucel, Muammer; Tutuncu, Neslihan Bascil; Guvener, Nilgun

Source: Clinical Endocrinology, Volume 67, Number 3, September 2007 , pp. 346-350(5)

Publisher: Blackwell Publishing

Molecule of the Month

Author: Anne Myers, Kari

Source: Current Topics in Medicinal Chemistry, Volume 7, Number 8, April 2007 , pp. 821-821(1)

Publisher: Bentham Science Publishers

Orlistat: A Review of its Use in the Management of Obesity

Authors: Henness, Sheridan; Perry, Caroline M.

Source: Drugs, Volume 66, Number 12, 2006 , pp. 1625-1656(32)

Publisher: Adis International

Fat Pills for Obesity's Ills: Novel Weight-Loss Drugs Emerging from the Pipeline

Author: Adis International Limited,

Source: Pharmaceutical & Diagnostic Innovation, Volume 4, Number 2, 2006 , pp. 7-9(3)

Publisher: Adis International

The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

Authors: Rowe, Rachel; Cowx, Margaret; Poole, Chris; McEwan, Phil; Morgan, Christopher; Walker, Mel

Source: Current Medical Research and Opinion, Volume 21, Number 11, November 2005 , pp. 1885-1890(6)

Publisher: Informa Healthcare

Orlistat for the treatment of obesity: cost utility model

Author: Foxcroft, D. R.

Source: Obesity Reviews, Volume 6, Number 4, November 2005 , pp. 323-328(6)

Publisher: Blackwell Publishing

Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and <it>PEA3</it>-mediated transcriptional repression of Her2/<it>neu</it> (<it>erb</it>B-2) oncogene

Authors: Menendez, J. A.; Vellon, L.; Lupu, R.

Source: Annals of Oncology, Volume 16, Number 8, August 2005 , pp. 1253-1267(15)

Publisher: Oxford University Press

The Committee for Medicinal Products for Human Use has granted orlistat [Xenical; Roche] a positive opinion in the EU

Source: Inpharma, Volume 1, Number 1489, 2005-05-28 , pp. 22-22(1)

Publisher: Adis International

New Zealanders can now purchase the weight loss drug orlistat [Xenical; Roche] over the counter (OTC) without a prescription

Source: Inpharma, Volume 1, Number 1479, 2005-03-19 , pp. 18-18(1)

Publisher: Adis International

New Zealanders can now purchase the weight loss drug orlistat [Xenical; Roche] over the counter (OTC) without a prescription

Source: PharmacoEconomics and Outcomes News, Volume 1, Number 474, 2005-03-26 , pp. 19-19(1)

Publisher: Adis International

Résultats de l’étude observationnelle EPIGRAM : prise en charge de l’obésité et du surpoids en médecine générale, suivi de la cohorte traitée par l’orlistat: Results from the Observational Study EPIGRAM: Management of Excess Weight in General Practice and Follow-Up of Patients Treated with Orlistat

Authors: Vray Muriel; Joubert Jean-Michel; Eschwège Eveline; Liard François; Fagnani Francis; Montestruc François; Fages Sophie; Bégaud Bernard

Source: Therapie, Volume 60, Number 1, 2005 , pp. 17-24(8)

Publisher: Adis International

Reclassification of orlistat [Xenical; Roche] as a pharmacist-only medicine has been recommended in New Zealand (NZ)

Source: Inpharma, Volume 1, Number 1474, 2005-02-12 , pp. 18-18(1)

Publisher: Adis International

Reduction of body weight and co-morbidities by orlistat: The XXL – Primary Health Care Trial

Author: Wirth, A.

Source: Diabetes, Obesity and Metabolism, Volume 7, Number 1, January 2005 , pp. 21-27(7)

Publisher: Blackwell Publishing

Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion

Authors: Nogueira Ferraz, Renato Ribeiro; Tiselius, Hans-Göran; Heiberg, Ita Pfeferman

Source: Kidney International, Volume 66, Number 2, August 2004 , pp. 676-682(7)

Publisher: Blackwell Publishing

EPIGRAM, étude pharmacoépidémiologique de l’obésité : méthodologie et critères de qualité: Methodology and Quality Control in EPIGRAM, a Pharmacoepidemiological Study of Obesity in General Practice

Authors: Muriel Vray; Jean-Michel Joubert; Eveline Eschwège; François Liard; Francis Fagnani; Bénédicte Commenges; Ghislaine Steinberg; Bernard Bégaud

Source: Therapie, Volume 59, Number 6, 2004 , pp. 573-579(7)

Publisher: Adis International

Clinical Pharmacotherapy for Obesity: Current Drugs and Those in Advanced Development

Author: Jason C.G. Halford

Source: Current Drug Targets, Volume 5, Number 7, October 2004 , pp. 637-646(10)

Publisher: Bentham Science Publishers

Natural abundance ¹³C-NMR spectroscopy for the quantitative determination of fecal fat

Authors: Kunz P.; Kunnecke B.; Kunz I.; Lengsfeld H.; von Kienlin M.

Source: Clinical Biochemistry, Volume 36, Number 7, October 2003 , pp. 505-510(6)

Publisher: Elsevier

Decreasing levels of tumour necrosis factor α and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

Authors: Samuelsson, L.; Gottsäter, A.; Lindgärde, F.

Source: Diabetes, Obesity and Metabolism, Volume 5, Number 3, May 2003 , pp. 195-201(7)

Publisher: Blackwell Publishing

Orlistat [`Xenical'; Roche] has been approved in Canada in a new indication

Source: Inpharma, Volume 1, Number 1325, 2002 , pp. 22-22(1)

Publisher: Adis International